Pilot and Feasibility Program

项目概要-试点和可行性方案 芝加哥糖尿病转化研究中心（CCDTR）的试点和可行性（P&F）资助计划 支持糖尿病翻译研究的新领域，特别关注改善护理和 弱势群体的结果。P&F计划的主要目的是为调查人员提供资金， 探索新的假设，并获得初步数据，以确保从传统的长期支持， 供资机制。来自P&F计划的资金支持了新的调查人员， 成为糖尿病转化研究的完全独立的科学家，并成为 寻求启动糖尿病相关研究。自2011年以来，CCDTR P&F已收到68份申请， 授予41笔赠款，导致52个摘要介绍，55个出版物，并资助NIDDK的29笔赠款， NHBLI，AHRQ，和其他。受赠者在随后的奖励中获得了2 500万美元的投资回报 每投资1美元就能获得28美元。P&F计划为许多调查人员带来了改变， 建立一个更加多样化和合作的研究人员网络，同时启动几个职业生涯 糖尿病转化研究领域的研究人员。赠款已发放给31名妇女（76%），23名妇女（56%）， 确定为种族/少数民族的调查人员，以及8个机构的19名（46%）有色人种女性， 12个部门。研究领域包括睡眠干预、终末期肾病患者的护理 疾病、移动的电话对久坐行为的干预以及以人为本的设计方法。看 未来，我们将通过与西北大学（NU）的新型合作伙伴关系扩大我们的影响力。这 合作伙伴关系将通过提供更广泛的覆盖面，进一步促进UC和NU一直在开展的工作 跨学科、跨机构、跨地域。此外，P&F计划将进一步加强， 扩大我们的范围，鼓励受助人申请：（1）正在测试新的健康干预措施 公平，传播和实施;（2）通过以下方式为糖尿病研究带来独特的视角： 非传统专业领域（如工程、设计、环境科学）;以及（3）确定为URM 和/或与URM服务和/或领导的利益相关者/社区组织合作。承认 P&F计划的重要性，UC和Feinberg学院生物科学部的院长 NU的医学将通过每年提供10万美元的配套资金来支持P&F计划。15万美元 我们每年将提供最多5笔2.5万美元的赠款和最多5笔5000美元的“迷你”赠款，以改善 参与和传播工作。迄今为止，我们的P&F计划的成功反映了 我们中心的跨学科性质和它提供的强大的研究基础。通过更新CCDTR 并与NU合作，P&F计划将能够继续提供必要的资金支持 新一代的创新和多样化的糖尿病翻译研究人员，并增加他们的机会， 确保未来长期融资。

PROJECT SUMMARY – Pilot and Feasibility Program The Pilot and Feasibility (P&F) grant program at the Chicago Center for Diabetes Translation Research (CCDTR) supports new areas of inquiry in diabetes translation research, with a special focus on improving the care and outcomes of vulnerable populations. The main aim of P&F program is to provide funding for investigators to explore novel hypotheses and to obtain preliminary data in order to secure long-term support from conventional funding mechanisms. Funding from the P&F program has supported new investigators who are seeking to become fully independent scientists in diabetes translation research and established investigators who are seeking to initiate diabetes-related research. Since 2011, the CCDTR P&F has received 68 applications and has awarded 41 grants, leading to 52 abstract presentations, 55 publications, and funding of 29 grants from NIDDK, NHBLI, AHRQ, and others. Grantees have received $25 million in subsequent awards with a return on investment of $28 for every $1 invested. The P&F program has made a difference for many investigators and has help establish a more diverse and collaborative network of researchers while launching the careers of several investigators in the fields of diabetes translational research. Grants have gone to 31 (76%) women, 23 (56%) investigators who identify as racial/ethnic minorities, and 19 (46%) women of color across eight institutions and 12 departments. The areas of study have included sleep interventions, care of patients with pre-end-stage kidney disease, mobile phone interventions on sedentary behavior, and human centered design approaches. Looking forward, we will amplify our reach through a novel partnership with Northwestern University (NU). This partnership will further catalyze the work that UC and NU have been conducting by providing broader reach across disciplines, institutions, and geography. Additionally, the P&F program will be furthered strengthened by expanding our scope by encouraging applications from grantees who: (1) are testing novel interventions in health equity, dissemination, and implementation; (2) bring unique perspective to diabetes research through nontraditional fields of expertise (e.g. engineering, design, environmental science); and (3) identify as URM and/or engage with stakeholders/community organizations that are URM serving and/or led. Acknowledging the importance of the P&F program, the Deans of the Biological Sciences Division at UC and Feinberg School of Medicine at NU will support the P&F program by providing $100K total in matching funds per year. With $150K funds per year, we will grant up to five grants of $25k per year and up to five “mini” grants of $5K to improve engagement and dissemination efforts. The success of our P&F program to date is a reflection of the interdisciplinary nature of our center and the strong research base it provides. Through a renewal of the CCDTR and collaboration with NU, the P&F program will be able to continue to provide necessary funding support to a new generation of innovative and diverse diabetes translation researchers and increase their chances of securing long-term funding in the future.